Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01012453
Other study ID # SJ-126
Secondary ID
Status Recruiting
Phase N/A
First received November 12, 2009
Last updated November 12, 2009
Start date October 2009

Study information

Verified date November 2009
Source Roskilde County Hospital
Contact Kristina Sophie Ibler, MD, Ph.d-student
Phone +45-47322600
Email ksi@regionsjaelland.dk
Is FDA regulated No
Health authority Denmark: The Regional Committee on Biomedical Research EthicsDenmark: Danish Dataprotection Agency
Study type Interventional

Clinical Trial Summary

Objectives and perspective:

1. To estimate the prevalence of hand eczema in a cohort of health care workers and assess exposures in the hospital environment that can lead to hand eczema . To investigate the knowledge of skin protection among health care workers.

2. To classify subtypes of hand eczema, assess severity of hand eczema and quality of life in health care workers with hand eczema

3. To evaluate the effect of a combination of classification of hand eczema and individual work-related counseling in skin protective behavior.

The overall perspective of the trial is to develop new strategies for prevention of occupational hand eczema in health care workers.

Hypotheses:

- Irritant contact dermatitis is more common than allergic contact dermatitis.

- The combination of precise classification (subtyping of HE) and individual counseling will have a positive impact on the prognosis of hand eczema.

- The positive impact on the prognosis of hand eczema will have a positive impact on quality of life (QoL).

- The knowledge of protective behavior will increase.

- Education in a skin care program will have a positive impact on skin protective behavior.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date
Est. primary completion date October 2009
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Participants will be recruited on the basis of the results from the questionnaire investigation of 3,181 HCW in three Danish hospitals in the same region. Participants who have answered "yes" to the validated question "Have you had hand eczema within the past twelve months?" will be invited to take part in the clinical trial.

- Informed written consent must be present in order to participate.

Exclusion Criteria:

- Pregnancy

- Systemic use of immunosuppressive drugs

- Systemic use of retinoids

- Active psoriatic lesions on the hands

- Any serious medical condition which, in the opinion of the investigator, may interfere with the evaluation of the results

- Lack of informed written consent

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Behavioral:
A randomised clinical trial of the effect of classification and individual counselling
The trial to be conducted is a randomised single-blinded parallel study. It is divided in two stages, T = 0 and follow-up at T = 6 months. All included participants will have a clinical examination at the beginning and at follow-up in the trial. Half of the participants will be randomised to intervention, the other half to control. The participants in the intervention group will, after the first clinical examination, pass on directly to the intervention which includes an allergological examination (patch and prick testing). Three days later they will be examined by a physician who will interpret the patch test and give a thorough, individual guidance in skin protection and occupational safety. The clinical examination of all participants at follow-up will reveal the difference in outcomes in the intervention and the control group.

Locations

Country Name City State
Denmark Holbaek Hospital Holbaek
Denmark Koege Hospital Koege
Denmark Dermatological Department, Roskilde County Hospital Roskilde

Sponsors (3)

Lead Sponsor Collaborator
Roskilde County Hospital Region Zealand, The Danish Working Environment Authority

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary outcome: Objective assessment of disease severity (HE), measured by HECSI-score at time = 6 months versus HECSI-score at time = 0. 6 months No
Secondary Secondary outcomes: -Subjective assessment of disease severity (HE) -Number of eruptions through the past three months -Knowledge of skin protection -Skinprotective behaviour -Quality of life 6 months No
See also
  Status Clinical Trial Phase
Completed NCT01257061 - Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment Phase 3
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Recruiting NCT05439577 - A Multicentre Study to Explore the Efficacy and Safety of Mucopolysaccharide Polysulfate Cream in Patients With Eczema
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT02075632 - Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream Phase 2
Completed NCT00143819 - Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis Phase 2
Recruiting NCT01631617 - Effects of Treatments on Atopic Dermatitis Phase 2
Completed NCT04358224 - The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment Phase 4
Not yet recruiting NCT04520308 - An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis Phase 4
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Completed NCT04023084 - Response of Children With Atopic Dermatitis (Eczema) to Eucrisa Phase 4
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Completed NCT05583019 - Atopic Dermatitis With Accelerometry and Polysomnography (ADAP)
Recruiting NCT03293030 - Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis Phase 4
Completed NCT02002871 - Blue Light for Treating Eczema N/A
Completed NCT01420705 - Bacille Calmette-Guérin (BCG) Vaccine and Atopy N/A
Completed NCT00375713 - Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema Phase 3
Recruiting NCT00177268 - Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research